hogfan's picks

[hogfan2]

$CUR...Neuralstem Inc.
TICKER: CUR:NYSE.MKT
Neuralstem Inc. is focused on developing and commercializing treatments for central nervous system diseases based on transplanting human neural stem cells and small molecule drugs. The company has developed and maintains a portfolio of patents and patent applications that form the base of its research and development efforts in neural stem cell research, small molecule research and related technologies. Neuralstem has also developed and patented a series of small molecule compounds (low molecular weight organic compounds) that can efficiently cross the blood/brain barrier. hide
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Expert Comments:
Larry Smith, SmithOnStocks (12/18/14) "Neuralstem Inc. has noted in response to questions that it appears to be seeing encouraging signs in the patients initially treated in the Chinese ischemic stroke trial; however, this is the very early 'dose up' part of the trial. In the U.S., this would be called a Phase 1b trial that treats patients suffering from the disease state as opposed to healthy volunteers."
Jason Napodano, Zacks Small-Cap Research (11/7/14) "The last patient has been treated in Neuralstem Inc.'s Phase 2 amyotrophic lateral sclerosis study, and data are expected during Q1/15. The first patient in the spinal cord injury study has been treated, and we expect continued enrollment of this trial in 2015." -Zacks Small-Cap Research
Jason Napodano, Seeking Alpha (10/15/14) "For the purpose of our financial model, we assume that if Neuralstem Inc.'s NSI-566 works, regardless of the entry criteria for the Phase 1 trial, neurosurgeons will use it in all patients and all areas of injury. . .as for the price of the surgery, we believe $150K is realistic. . .if we apply these data in a detailed epidemiology and pricing model, with 5% U.S. market share, NSI-566 is a potential $500M drug."
Reni Benjamin, H.C. Wainwright & Co. (10/13/14) "Last Thursday, Neuralstem Inc. announced that the first of four chronic spinal cord injury patients in a Phase 1 trial of NSI-566 was recently treated at the University of California, San Diego School of Medicine. . .we view the forward progress of the trial as welcome news for investors; it marks a foray into an indication area with a potentially addressable patient population nearly 10 times that of amyotrophic lateral sclerosis."
Ram Selvaraju, Aegis Capital (10/9/14) "This morning, Neuralstem Inc. announced that the first patient was treated last week in the firm's Phase 1 trial testing NSI-566. . .we are encouraged to see the initiation of this important clinical program, and believe that preclinical evidence of NSI-566 therapeutic efficacy is particularly strong in the context of spinal cord injury."
fewer comments
Reni Benjamin, H.C. Wainwright & Co. (9/23/14) "Dr. Glass of Emory University presented positive long-term follow-up data of a subset of patients from the Phase 1 trial of NSI-566 testing Neuralstem Inc.'s human neural stem cells in Amyotrophic Lateral Sclerosis (ALS). . .together, the data continue to suggest that NSI-566 treatment can slow the progression of the disease for over three years in ambulatory patients given bilateral injections of NSI-566 cells in the lumbar and cervical spine. . .if the above results are successfully replicated in the ongoing Phase 2 trial in ALS, we believe NSI-566 could represent a treatment capable of producing long lasting and durable responses in this progressive and invariably fatal neurological disease."
Larry Smith, SmithOnStocks (9/23/14) "The key investigators for the treatment of amyotrophic lateral sclerosis (ALS) with Neuralstem Inc.'s NSI-566 neural stem cells have been extremely positive in public statements; they are Dr. Eva Feldman, the lead investigator for the trial, and Dr. Jonathan Glass. Feldman is professor of medicine at the University of Michigan Health Care System and past president of the American Neurological Association; Glass is director of the Emory ALS Center at Emory University."
Reni Benjamin, H.C. Wainwright & Co. (9/8/14) "We are initiating coverage on Neuralstem Inc. . .the major investment pros are: a lead product that potentially addresses unmet global medical needs, orphan drug status in amyotrophic lateral sclerosis, a pipeline with multiple products in various stages of early clinical development and an excellent safety profile based on multiple Phase 1 and 2 studies."
The Life Sciences Report Interview with Raghuram Selvaraju (8/13/14) "Neuralstem Inc. has been in the process of running a Phase 2 proof-of-concept study in amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. It's an orphan disease. There is no effective therapy, and after diagnosis, patients typically die within three to six years.

Neuralstem's stem cell-based solution, NSI-566 (human fetal spinal cord-derived stem cells), has been widely anticipated. The Phase 1/2 data, published in the peer-reviewed journal Annals of Neurology, showed anecdotal evidence of efficacy, which was encouraging. If these Phase 2 data, expected from all cohorts in early 2015, show signs of the same kind of efficacy, that would go a long way toward convincing the FDA that NSI-566 should receive breakthrough therapy designation. NSI-566 could then be fast-tracked toward approval. . ." More >
Ram Selvaraju, Aegis Capital (8/8/14) "Neuralstem Inc. reported financial results for Q2/14, ending the period with $30.2M in cash. We expect this to be sufficient to fund operations through 2015. . .the company essentially delivered an in line quarter."
Jason Napodano, Zacks Small-Cap Research (8/8/14) "Neuralstem Inc. exited Q2/14 ending June 30, 2014 with $30.2M in cash and investments. Based on the current quarterly burn rate, less debt repayments, we believe this is enough cash to fund operations into the middle of 2016." -Zacks Small-Cap Research
Ram Selvaraju, Aegis Capital (8/4/14) "This morning, Neuralstem Inc. announced that the final patient had been treated in its Phase 2 study of NSI-566, a novel stem cell-based therapeutic agent, assessing individuals with amyotrophic lateral sclerosis. . .the trial will continue until six months past the final surgery, at which point the data will be evaluated. In anticipation of favorable efficacy results from this Phase 2 trial of NSI-566, we reiterate our Buy rating and 12-month price target of $7/share."
Jason Napodano, Zacks Small-Cap Research (6/25/14) "Data from Neuralstem Inc.'s Phase 1b, randomized, double-blind, placebo-controlled, multiple-dose escalation study evaluating the effects of NSI-189 in patients with major depressive disorder was presented via an oral presentation and poster at two major neuropharmacology meetings earlier this month. . .in terms of a Phase 1b study, [data] looks very good. Safety was confirmed and there are clear trends toward efficacy. . .we continue to be optimistic on the future of Neuralstem."
Ram Selvaraju, Aegis Capital (6/25/14) "We are raising our price objective on Neuralstem Inc. in the wake of favorable safety and efficacy data. . .these data validate the company's hypothesis that NSI-189 has activity as both a cognitive function enhancer and an antidepressant. . .we reiterate our Buy rating and raise our 12-month price target from $6 to $7/per share."

http://www.thelifesciencesreport.com/pub/co/4857